Yes, this is the result of the S-3 shelf offering that was declared effective Oct. 24, 2017.
Hoping it will make for a great buy opportunity.
This is from Jan 8 and is very positive growth. Funding should hep it continue accelerating.
" a neurostimulation medical device company, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2017.
Preliminary unaudited fourth quarter consolidated revenue is expected to be in the range of $11.5 to $12.0 million, compared to $4.2 million in the fourth quarter of 2016. Preliminary unaudited Algovita revenue for the fourth quarter of 2017 is expected to be in the range of $10.0 to $10.5 million, compared to $2.0 million in the fourth quarter of 2016.
Nuvectra’s preliminary unaudited full year 2017 consolidated revenue is expected to be in the range of $31.5 to $32.0 million, compared to $12.5 million for full year 2016."
Another potential benefit is increasing the o/s shares and liquidity making it more tradable.
News 
Market Data 
Discover 
